Filing Details
UroGen Pharma Ltd. (NASDAQ:URGN) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 05, 2026.
The Healthcare company reported Q0 revenue of .
10q filedNASDAQ:URGN
UroGen Pharma Ltd. (URGN) Files Quarterly Report for Q0
Filing Details UroGen Pharma Ltd. (NASDAQ:URGN) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 05, 2026. The Healthcare company…
Market Context
UroGen Pharma Ltd.'s stock currently trades at $46.43 with a market capitalization of $1.0B.
The 10-Q provides UroGen Pharma Ltd.'s quarterly financial update, including unaudited financial statements and management commentary on recent performance. While less detailed than the annual 10-K, the 10-Q often contains timely information about emerging trends, updated risk factors, and changes in business conditions since the last filing.
All SEC filings for UroGen Pharma Ltd. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View URGN Stock Page
Frequently Asked Questions
Where can I read URGN's SEC filings?
Browse all filings on our URGN SEC filings page.
What types of SEC filings does UroGen Pharma Ltd. file?
Public companies like UroGen Pharma Ltd. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.
